George B. Breen, Chair of the firm’s National Health Care and Life Sciences Practice Steering Committee, in the Washington, DC, office, David E. Matyas, Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, and Daniel C. Fundakowski, Associate in the Health Care and Life Sciences practice, in the Washington, DC, office, authored an article in Law360 titled “Key FCA Developments for Health Care in 2014.” (Read the full version—subscription required.)
Following is an excerpt:
On Nov. 20, 2014, the U.S. Department of Justice announced settlements and judgments for False Claims Act cases totaling $5.7 billion (compared to $3.8 billion in fiscal year 2013), $2.3 billion of which was derived from the health care sector. Earlier this fall, the DOJ announced that all new FCA qui tam complaints will be automatically reviewed by both the DOJ’s criminal division and its civil division — the criminal division no longer being reliant on referrals for potential prosecution. With this enforcement background, 2014 is marked by a number of key FCA developments that are significant to the health care industry.